Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission

Reuters

05-21

Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission

Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug $(IND.AU)$ submission to the U.S. Food and Drug Administration (FDA) later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder (PTSD) and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455536-en) on May 21, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537933163"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537933163\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537933163?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537933163","market":"nz","top_or_hot":-1,"title":"Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> submission to the U.S. Food and Drug Administration (FDA) later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder (PTSD) and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455536-en) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> submission to the U.S. Food and Drug Administration (FDA) later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder (PTSD) and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455536-en) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL7464vq:1","article_id":"2537933163","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537933163","pubTimestamp":1747832112,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug  submission to the U.S. Food and Drug Administration  later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder  and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4202":"服装、服饰与奢侈品","SILO":"SILO PHARMA INC.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Silo Pharma启动用于PTSD治疗的鼻内药物器械研究，与Resyca合作提交IND","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SILO":0.9},"content_text":"Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission\n    \n\n        Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug $(IND.AU)$ submission to the U.S. Food and Drug Administration (FDA) later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder (PTSD) and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455536-en) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}